Recap: Arcadia Biosciences Q4 Earnings
Portfolio Pulse from Benzinga Insights
Arcadia Biosciences (NASDAQ:RKDA) reported Q4 earnings with an EPS of $-2.1, beating estimates by 19.0% against an expected $-2.58. Revenue increased by $170 thousand from the same period last year. Despite beating EPS estimates last quarter, RKDA's share price dropped by 3.0% the following day. The company's past earnings performance shows a mixed trend with both beats and misses on EPS and revenue estimates.
March 28, 2024 | 9:30 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Arcadia Biosciences reported a Q4 EPS of $-2.1, beating estimates by 19.0%, with a revenue increase of $170 thousand YOY. Despite a history of beating EPS estimates, share price experienced a drop following last quarter's earnings.
While RKDA beat its Q4 earnings estimates, which could be seen as a positive signal, the company's history of share price dropping after beating last quarter's EPS suggests a cautious outlook. The mixed past performance and the recent beat might not be enough to drive a significant positive sentiment in the short term, hence the neutral score.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100